Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT06236295
PHASE2
Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
This is a multicenter, single-arm, long-term safety and tolerability trial. A total of 300 subjects with chronic kidney disease on hemodialysis are planned to be enrolled.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
303
Start Date
2024-02-20
Completion Date
2025-11-13
Last Updated
2026-05-20
Healthy Volunteers
No
Conditions
Interventions
DRUG
SHR6508
SHR6508 will be administered to all the eligible subjects
Locations (1)
Peking University People's Hospital
Beijing, Beijing Municipality, China